Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix IPV
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix IPV is a combination vaccine developed by GSK for the active immunization of infants and children against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. It is a tetravalent vaccine containing diphtheria and tetanus toxoids, three purified acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin), and inactivated poliovirus types 1, 2, and 3. The vaccine works by stimulating the immune system to produce specific antibodies against the bacterial toxins of Corynebacterium diphtheriae and Clostridium tetani, the antigenic components of Bordetella pertussis, and the three types of poliovirus. Infanrix IPV is typically administered as an intramuscular injection and is used as part of a primary vaccination series or as a booster dose. It also serves as a base for more complex combination vaccines, such as the pentavalent Infanrix-IPV+Hib.
- Brand names
- Infanrix IPV
- Other names
- Infanrix-IPVDiphtheria, Tetanus, Pertussis (Acellular), and Poliomyelitis (Inactivated) Vaccine (Adsorbed)
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix IPV.